Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New heart scan could spare patients from invasive artery checks

NCT ID NCT05940285

Diagnosis Sponsor: Nantes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study is testing whether a special heart scan (dynamic SPECT) can accurately detect remaining blockages in heart arteries after a heart attack, compared to the current standard invasive procedure (FFR). Sixty adults with multiple blocked arteries will receive both tests one month after their heart attack. The goal is to see if the non-invasive scan can reliably replace the invasive one, making follow-up safer and more comfortable.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dynamic 99mTc-Tetrofosmin CZT-SPECT (a radioactive tracer used in a heart scan)
What this could lead to
If successful, this could allow doctors to use a simple, non-invasive scan instead of a risky invasive procedure to check for remaining blockages after a heart attack.
What could go wrong
This is a small pilot study with only 60 participants, so results may not apply to everyone. The new scan might not be accurate enough to replace the invasive test in all cases.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 60 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2023

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult patient. * Multi vessel coronary arteries disease (at least one non-culprit coronary stenosis \>= 50%) diagnosis during * primary percutaneous coronary intervention \< 12h after ST-elevation myocardial infarction opercutaneous revascularisation of the culprit lesion within 24 to 48 hours of an acute non-ST-segment elevation coronary syndrome. * Written consent. * Social security affiliation Exclusion Criteria: * Non adult patient. * Adult patient under tutelage. * Reproductive age women. * Medical history of myocardial infarction or coronary artery bypass surgery. * Cardiogenic shock. * Cardiomyopathy. * Regadenoson/adenosine/FFR contraindication. * 99mTc-Tetrofosmin hypersensibility. * Small non-culprit coronary arteries. * Participation to another interventional study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Myocardial infarction are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute coronary syndrome myocardial infarction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Myocardial infarction

Contacts and locations

Locations

  • Nantes University Hospital

    Nantes, 44093, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.